Natera, Inc. (NASDAQ:NTRA) Shares Sold by National Bank of Canada FI

National Bank of Canada FI lessened its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 94.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,593 shares of the medical research company's stock after selling 78,996 shares during the quarter. National Bank of Canada FI's holdings in Natera were worth $583,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the second quarter worth $28,000. Quarry LP lifted its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after buying an additional 190 shares during the period. Covestor Ltd boosted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC grew its holdings in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after acquiring an additional 106 shares during the period. Finally, True Wealth Design LLC purchased a new position in Natera during the third quarter valued at approximately $57,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Natera

In other Natera news, insider Jonathan Sheena sold 3,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $125.67, for a total value of $377,010.00. Following the transaction, the insider now owns 57,432 shares of the company's stock, valued at $7,217,479.44. This represents a 4.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Rowan E. Chapman sold 1,767 shares of Natera stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total transaction of $300,814.08. Following the sale, the director now owns 6,202 shares of the company's stock, valued at approximately $1,055,828.48. This represents a 22.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 132,963 shares of company stock worth $21,250,107. Insiders own 7.60% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. Robert W. Baird upped their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group boosted their price objective on Natera from $150.00 to $165.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $152.67.

Natera Trading Up 2.6 %

NASDAQ NTRA traded up $4.25 on Monday, reaching $170.80. 1,378,811 shares of the company were exchanged, compared to its average volume of 1,330,675. Natera, Inc. has a fifty-two week low of $57.22 and a fifty-two week high of $175.63. The stock has a market capitalization of $22.55 billion, a P/E ratio of -97.05 and a beta of 1.63. The business's fifty day moving average price is $144.87 and its 200 day moving average price is $125.09. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue was up 63.9% compared to the same quarter last year. During the same period last year, the business earned ($0.95) earnings per share. Analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.